Latest news with #pulmonaryfibrosis
Yahoo
24-05-2025
- Health
- Yahoo
Siblings battling lung disease raise awareness
A brother and sister with a rare lung disease which leaves them struggling for breath are raising awareness of the condition. Joanne Lovejoy-Waud and Mark Waud were diagnosed with pulmonary fibrosis (PF) at the ages of 52 and 59, respectively. Their father Bernard Waud died from the condition when he was 50 years old. Mrs Lovejoy-Waud, from Goole, said more than 30 years after her father's death there was still no cure for the disease. The Pulmonary Fibrosis Trust said the "rare" disease has an average life expectancy of between three-to five years after diagnosis and in the majority of cases, the cause was unknown. Mark Waud was diagnosed with idiopathic pulmonary fibrosis (IPF) in April 2024 and said he had 12 months to live. His constant companion is a black bag containing a canister filled with life-saving oxygen. During the interview, the 60-year-old from Wakefield paused often to cough and sip water to lubricate his throat. Physical movement, like climbing the stairs, can trigger a "coughing fit to a stage where I'd literally induce a panic attack because you literally can't breath. It feels like somebody's sat on your chest," he said. On receiving his diagnosis, he said: "It wasn't too much of a shock, because my sister had been diagnosed two years earlier." His sister Joanne Lovejoy-Waud sought medical advice after coughing up blood. On receiving the diagnosis she said "as we (Nicola Lovejoy-Ward) were driving home, we felt numb". Like her brother, Joanne Loveday-Waud is dependant on oxygen. "I can't remember breathing normally without it. It's a way of life," she said. A tube attached to her nostrils fills her lungs with liquid oxygen. "I can feel the cold oxygen passing through my nose. It (the tubes) makes my nose and behind my ears sore. It's uncomfortable at first, but you get used to it." The 55-year-old was active, but the progressive disease dictates how she will live the remainder of her life. "I can't walk more than 10m (32ft) without oxygen." "The worst thing about this disease is the anxiety when people are looking at you and staring while you've got your oxygen on," she added. Nicola Lovejoy-Waud and her wife are organising an annual event called Picnic in the Park in West Park, Goole on 1 June to help raise awareness of IPF. "We know that not many people have heard of pulmonary fibrosis, not a lot of people know what the Pulmonary Fibrosis Trust do. So, we raise awareness to promote and gain funding." Peter Bryce chair of Pulmonary Fibrosis Trust said more than 6,000 people die from PF each year in the UK. The symptoms include shortness of breath, fatigue and a persistent dry cough. "I do not know why there is so little awareness of this dreadful condition. "The number of people living with PF is considerably less than some lung conditions, but as the prognosis is so poor, it should have wider concern," he added. There are thought to be 200 different causes of PF, including genetic. The siblings have a form of PF known as idiopathy - which means cause unknown. Joanne Lovejoy-Waud is being assessed for a lung transplant and was aware of the long transplant waiting list. Meanwhile, Mr Waud, who has liquid morphine for pain control, said because of the risks involved with a transplant he was "undecided". For Joanne's wife Nicola, the emotional trauma of having two relatives with a life limiting condition is hard to bear. She said: "It's like a black cloud hanging over us because you don't know when that time is going to come. "Ultimately, I'll have two funerals to attend. One being my wife and one being my brother-in-law," she added. Listen to highlights from Hull and East Yorkshire on BBC Sounds, watch the latest episode of Look North or tell us about a story you think we should be covering here. Lung transplant recipient thanks 'true hero' donor Funding plea for rare lung disease Coronavirus could leave thousands with lung damage Pulmonary Fibrosis Trust British Lung Foundation
BBC News
24-05-2025
- Health
- BBC News
Pulmonary fibrosis: Lung disease siblings battling to breathe
A brother and sister with a rare lung disease which leaves them struggling for breath are raising awareness of the Lovejoy-Waud and Mark Waud were diagnosed with pulmonary fibrosis (PF) at the ages of 52 and 59, respectively. Their father Bernard Waud died from the condition when he was 50 years old. Mrs Lovejoy-Waud, from Goole, said more than 30 years after her father's death there was still no cure for the disease. The Pulmonary Fibrosis Trust said the "rare" disease has an average life expectancy of between three-to five years after diagnosis and in the majority of cases, the cause was unknown. 'Can't breathe' Mark Waud was diagnosed with idiopathic pulmonary fibrosis (IPF) in April 2024 and said he had 12 months to constant companion is a black bag containing a canister filled with life-saving the interview, the 60-year-old from Wakefield paused often to cough and sip water to lubricate his movement, like climbing the stairs, can trigger a "coughing fit to a stage where I'd literally induce a panic attack because you literally can't breath. It feels like somebody's sat on your chest," he receiving his diagnosis, he said: "It wasn't too much of a shock, because my sister had been diagnosed two years earlier." Coughing up blood His sister Joanne Lovejoy-Waud sought medical advice after coughing up blood. On receiving the diagnosis she said "as we (Nicola Lovejoy-Ward) were driving home, we felt numb". Like her brother, Joanne Loveday-Waud is dependant on oxygen. "I can't remember breathing normally without it. It's a way of life," she said.A tube attached to her nostrils fills her lungs with liquid oxygen. "I can feel the cold oxygen passing through my nose. It (the tubes) makes my nose and behind my ears sore. It's uncomfortable at first, but you get used to it."The 55-year-old was active, but the progressive disease dictates how she will live the remainder of her life. "I can't walk more than 10m (32ft) without oxygen.""The worst thing about this disease is the anxiety when people are looking at you and staring while you've got your oxygen on," she added. Nicola Lovejoy-Waud and her wife are organising an annual event called Picnic in the Park in West Park, Goole on 1 June to help raise awareness of IPF."We know that not many people have heard of pulmonary fibrosis, not a lot of people know what the Pulmonary Fibrosis Trust do. So, we raise awareness to promote and gain funding."Peter Bryce chair of Pulmonary Fibrosis Trust said more than 6,000 people die from PF each year in the UK. The symptoms include shortness of breath, fatigue and a persistent dry cough."I do not know why there is so little awareness of this dreadful condition. "The number of people living with PF is considerably less than some lung conditions, but as the prognosis is so poor, it should have wider concern," he added. 'Black cloud' There are thought to be 200 different causes of PF, including siblings have a form of PF known as idiopathy - which means cause Lovejoy-Waud is being assessed for a lung transplant and was aware of the long transplant waiting Mr Waud, who has liquid morphine for pain control, said because of the risks involved with a transplant he was "undecided".For Joanne's wife Nicola, the emotional trauma of having two relatives with a life limiting condition is hard to said: "It's like a black cloud hanging over us because you don't know when that time is going to come."Ultimately, I'll have two funerals to attend. One being my wife and one being my brother-in-law," she added. Listen to highlights from Hull and East Yorkshire on BBC Sounds, watch the latest episode of Look North or tell us about a story you think we should be covering here.
Yahoo
24-05-2025
- Health
- Yahoo
Siblings battling lung disease raise awareness
A brother and sister with a rare lung disease which leaves them struggling for breath are raising awareness of the condition. Joanne Lovejoy-Waud and Mark Waud were diagnosed with pulmonary fibrosis (PF) at the ages of 52 and 59, respectively. Their father Bernard Waud died from the condition when he was 50 years old. Mrs Lovejoy-Waud, from Goole, said more than 30 years after her father's death there was still no cure for the disease. The Pulmonary Fibrosis Trust said the "rare" disease has an average life expectancy of between three-to five years after diagnosis and in the majority of cases, the cause was unknown. Mark Waud was diagnosed with idiopathic pulmonary fibrosis (IPF) in April 2024 and said he had 12 months to live. His constant companion is a black bag containing a canister filled with life-saving oxygen. During the interview, the 60-year-old from Wakefield paused often to cough and sip water to lubricate his throat. Physical movement, like climbing the stairs, can trigger a "coughing fit to a stage where I'd literally induce a panic attack because you literally can't breath. It feels like somebody's sat on your chest," he said. On receiving his diagnosis, he said: "It wasn't too much of a shock, because my sister had been diagnosed two years earlier." His sister Joanne Lovejoy-Waud sought medical advice after coughing up blood. On receiving the diagnosis she said "as we (Nicola Lovejoy-Ward) were driving home, we felt numb". Like her brother, Joanne Loveday-Waud is dependant on oxygen. "I can't remember breathing normally without it. It's a way of life," she said. A tube attached to her nostrils fills her lungs with liquid oxygen. "I can feel the cold oxygen passing through my nose. It (the tubes) makes my nose and behind my ears sore. It's uncomfortable at first, but you get used to it." The 55-year-old was active, but the progressive disease dictates how she will live the remainder of her life. "I can't walk more than 10m (32ft) without oxygen." "The worst thing about this disease is the anxiety when people are looking at you and staring while you've got your oxygen on," she added. Nicola Lovejoy-Waud and her wife are organising an annual event called Picnic in the Park in West Park, Goole on 1 June to help raise awareness of IPF. "We know that not many people have heard of pulmonary fibrosis, not a lot of people know what the Pulmonary Fibrosis Trust do. So, we raise awareness to promote and gain funding." Peter Bryce chair of Pulmonary Fibrosis Trust said more than 6,000 people die from PF each year in the UK. The symptoms include shortness of breath, fatigue and a persistent dry cough. "I do not know why there is so little awareness of this dreadful condition. "The number of people living with PF is considerably less than some lung conditions, but as the prognosis is so poor, it should have wider concern," he added. There are thought to be 200 different causes of PF, including genetic. The siblings have a form of PF known as idiopathy - which means cause unknown. Joanne Lovejoy-Waud is being assessed for a lung transplant and was aware of the long transplant waiting list. Meanwhile, Mr Waud, who has liquid morphine for pain control, said because of the risks involved with a transplant he was "undecided". For Joanne's wife Nicola, the emotional trauma of having two relatives with a life limiting condition is hard to bear. She said: "It's like a black cloud hanging over us because you don't know when that time is going to come. "Ultimately, I'll have two funerals to attend. One being my wife and one being my brother-in-law," she added. Listen to highlights from Hull and East Yorkshire on BBC Sounds, watch the latest episode of Look North or tell us about a story you think we should be covering here. Lung transplant recipient thanks 'true hero' donor Funding plea for rare lung disease Coronavirus could leave thousands with lung damage Pulmonary Fibrosis Trust British Lung Foundation
Medscape
20-05-2025
- Health
- Medscape
Less FVC Decline in Progressive PF With Oral Nerandomilast
SAN FRANCISCO — The investigational oral agent nerandomilast was superior to placebo at slowing the decline in forced vital capacity (FVC) among patients with progressive pulmonary fibrosis (PF), results of the phase 3 randomized FIBRONEER-ILD trial showed. Among 1176 patients, the mean decline from baseline in FVC at 1 year was significantly greater for those assigned to receive a placebo than those assigned to receive nerandomilast at either of two doses, reported Marlies S. Wijsenbeek, MD, PhD, from Erasmus Medical Center in Rotterdam, the Netherlands. 'I think, personally, that these results are really a major step forward. After a decade of failed phase 3, we have now a positive trial which is really important for treatment of people with IPF [idiopathic PF],' she said in oral abstract session at American Thoracic Society (ATS) 2025 International Conference. The study was also published online in The New England Journal of Medicine to coincide with the presentation. Phosphodiesterase 4B (PDE-4B) Inhibitor Nerandomilast is an oral preferential inhibitor of PDE-4B that has shown both antifibrotic and immunomodulatory effects in preclinical models. In a phase 3 follow-on trial of this agent in patients with IPF (FIBRONEER-IPF), nerandomilast was associated with a smaller decline in FVC compared with placebo over 1 year. In FIBRONEER-ILD, which was conducted at 403 sites in 44 countries, patients with fibrosing interstitial lung disease (ILD) other than IPF were enrolled. After stratification by prior nintedanib (OFEV) use and high-resolution CT pattern (either usual interstitial pneumonia [UIP] or UIP-like fibrotic pattern vs other fibrotic patterns), patients were randomized in a 1:1:1 ratio to receive either nerandomilast twice daily at doses of 18 or 9 mg or placebo. Approximately 44% of patients in each study arm were on nintedanib background therapy. The adjusted mean change in FVC at week 52, the primary endpoint, was −98.6 mL for patients assigned to nerandomilast 18 mg, −84.6 mL for those assigned to nerandomilast 9 mg, and −165.8 mL for those assigned to placebo. The adjusted difference between 9-mg nerandomilast and placebo groups was 81.1 mL ( P < .001), and the adjusted difference between 18-mg and placebo groups was 67.2 mL ( P < .001). The effect of nerandomilast was generally consistent across ILD subtypes, Wijsenbeek said. At the time of data cutoff, a first acute exacerbation of ILD, hospitalization for a respiratory cause, or death — a key composite secondary endpoint — occurred in 95 patients on the 18-mg dose, 110 on the 9-mg dose, and 122 patients on placebo. These differences did not reach statistical significance, however. A total of 24 patients in the 18-mg group (6.1%), 33 in the 9-mg group (8.4%), and 50 in the placebo group (12.8%) died during the study. The hazard ratio for death among patients in the 18-mg vs placebo group was 0.48 (95% CI, 0.30-0.79), and the hazard ratio for the 9-mg vs placebo group was 0.60 (95% CI, 0.38-0.95). Diarrhea, the most common adverse event, was reported in 36.6% of patients taking 18 mg nerandomilast twice daily, 29.5% of those taking 9 mg twice daily, and 24.7% of those on placebo. Diarrhea leading to discontinuation was also higher in both the nerandomilast dosing groups than in the placebo group. In the question and answer following her talk, Gisli Jenkins, MD, PhD, from Imperial College London, London, England, asked Wijsenbeek whether slowing absolute decline in FVC was the best endpoint for the trial. 'I think there is a lot of debate [about] what is the best endpoint. I think it's the best endpoint we currently have,' she replied. Ganesh Raghu, MD, from the University of Washington in Seattle, commented that FIBRONEER-ILD efficacy data were similar to those seen a decade ago with nintedanib and asked Wijsenbeek whether she could put the new data in context with existing therapies. She replied that although the efficacy of the agents are similar, patients appear to tolerate nerandomilast better than nintedanib, 'so that's a gain, in my opinion.' She added that any additional clinical benefit, even if it's only incremental, is better for patients, and she noted that although the study was not powered to detect a decrease in acute exacerbations, hospitalizations, or deaths, the data pointed to a benefit for nerandomilast. In an editorial accompanying the study in NEJM , Joyce S. Lee, MD, from the University of Colorado Anschutz Medical Campus in Aurora, Colorado, commented that the FIBRONEER-IPF and FIBRONEER-ILD trials 'represent a meaningful advancement in the treatment landscape for persons living with IPF and progressive ILD other than IPF. Important issues that our community of clinicians will need to address moving forward nonetheless remain — decisions regarding the choice of first-line therapy, indications for up-front combination therapy as compared with add-on therapy, and the role of immunosuppression in patients with non-IPF ILD and a PPF phenotype.' The study was supported by Boehringer Ingelheim. Wijsenbeek reported serving on a scientific advisory board and receiving speaker fees and unrestricted grants, all paid to her institution and not her personally. Lee and Jenkins reported having financial relationships with Boehringer Ingelheim and others. Raghu disclosed advisory board/consulting activities for various companies, not including Boehringer Ingelheim.
Yahoo
06-05-2025
- Business
- Yahoo
Avalyn Announces Multiple Presentations on AP01 and AP02 for Pulmonary Fibrosis at the American Thoracic Society 2025 International Conference
Avalyn Pharma Inc. Topline Results from the AP02 (Inhaled Nintedanib) Phase 1 Clinical Trials Among the Company's Five Poster Presentations 4.5 Year Long-Term Safety and Efficacy Data Supporting AP01 (Inhaled Pirfenidone) from the ATLAS Open-Label Extension Trial to be Presented Avalyn to be featured in ATS Industry Theater Program CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced multiple presentations at the American Thoracic Society (ATS) 2025 International Conference being held May 16-21, 2025, at the Moscone Center in San Francisco, CA. 'We're proud to showcase a strong portfolio of presentations at the upcoming ATS conference, which reflects the dedication of our team and collaboration with physicians and medical professionals to meet the urgent therapeutic needs in the pulmonary fibrosis community,' said Lyn Baranowski, CEO of Avalyn Pharma. 'We look forward to reporting topline data from two Phase 1 clinical trials of AP02, which support its advancement into a Phase 2 trial, and up to 240 weeks of long-term clinical efficacy and safety data on AP01. Our presence at ATS will showcase our belief that we are well-positioned to transform how pulmonary fibrosis will be treated in the future through the advent of optimized inhaled formulations that offer improved safety, efficacy and long-term adherence – a critical must-have given the progressive, chronic nature of this disease.' Avalyn's presentations will include topline data from the single- and multiple-ascending dose Phase 1 clinical trials of AP02 (inhaled nintedanib) in healthy adult volunteers and patients with idiopathic pulmonary fibrosis (IPF) and new long-term safety and efficacy data from the ATLAS open-label extension trial of AP01 (inhaled pirfenidone) in patients with IPF and progressive pulmonary fibrosis (PPF). Furthermore, the company, in collaboration with Qureight, will present results from two deep learning-based analyses of high-resolution computed tomography (HRCT) scans and patient data from the Phase 1b ATLAS trial of AP01, exploring the utility of novel imaging biomarkers and synthetic study arms in validating treatment efficacy in patients with IPF. Avalyn will also be featured in the ATS Industry Theater program, where Joyce Lee, M.D., Professor of Medicine in Pulmonary Sciences and Critical Care Medicine, Director of the Interstitial Lung Disease Program, University of Colorado School of Medicine, an investigator in the Phase 2b clinical trial of AP01, and a steering committee member for AP02, will provide data highlights from the Phase 1 clinical trials of AP02.
